TL;DR
The commercial landscape for obesity care is shifting toward cash-pay and government-discount models as major health insurers begin dropping coverage for their own workforces. Meanwhile, clinical data from the American Diabetes Association (ADA) 2026 Scientific Sessions highlights a growing tension between extreme weight-loss potency and patient tolerability, paving the way for next-generation amylin-based therapies to challenge GLP-1 dominance.
Commercial Insurance Retreat and the Rise of Cash-Pay
The financial strain of funding obesity therapies is forcing commercial plan sponsors to abandon traditional coverage in favor of direct-to-consumer and government-backed discount pathways.
"As availability has increased and new options have emerged, we've made the decision to end our plan's coverage for GLP-1s for weight loss. We remain committed to supporting our employees’ health through a range of weight management programs and resources."
— cigna-drops-employee-glp1-coverage-trumprx-cash-pay-2026
According to Reuters coverage of the June 1, 2026 announcement, Cigna is dropping coverage for Novo Nordisk's Wegovy and Eli Lilly's Zepbound for its own employees cigna-drops-employee-glp1-coverage-trumprx-cash-pay-2026. Instead, Cigna is directing employees to utilize manufacturer direct sites or the federal TrumpRx platform, where brand-name GLP-1s are available for $350 per month and newer oral medications are priced as low as $150 per month cigna-drops-employee-glp1-coverage-trumprx-cash-pay-2026.
By removing these blockbuster therapies from commercial benefit designs, major payers are signaling that obesity management is transitioning from an insured benefit to a cash-pay consumer market. This shifts the financial burden directly to patients while highlighting the growing influence of federally facilitated pricing platforms.
What to watch: Watch whether other major healthcare employers and pharmacy benefit managers follow Cigna's lead in dropping employee weight-loss coverage as the TrumpRx platform gains commercial traction.
Efficacy Milestones Collision with Tolerability Barriers
The race for extreme weight-loss potency is hitting a critical clinical ceiling as maximum efficacy comes at the cost of high patient dropouts and severe gastrointestinal side effects.
"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos. In TRIUMPH-1 and TRANSCEND-T2D-1, treatment with retatrutide resulted in substantial weight reduction together with clinically meaningful improvements in glycemia, knee osteoarthritis pain, and obstructive sleep apnea..."
— retatrutide-phase3-triumph1-results-30-percent
As reported by Fierce Biotech coverage of the ADA sessions, Eli Lilly's retatrutide achieved historic weight loss of 30.3% in its long-term trial extension, but also brought significant tolerability hurdles, particularly at the highest dose, where nausea affected 42.4% of participants retatrutide-phase3-triumph1-results-30-percent. This heavy side-effect profile resulted in a notable 11.3% discontinuation rate due to adverse events at the maximum 12 mg dose retatrutide-phase3-triumph1-results-30-percent.
While achieving surgery-like weight reduction is a massive scientific milestone, real-world utility will be bottlenecked if over a tenth of patients cannot tolerate the therapy. Drug developers must balance absolute potency against patient compliance to secure long-term commercial success.
What to watch: Watch whether clinicians increasingly favor lower, more tolerable doses of retatrutide over the maximum 12 mg dose in real-world practice.
Amylin Emerges to Challenge GLP-1 Dominance
Drug developers are rapidly advancing amylin-targeting therapies as a highly tolerable alternative or potent co-agonist to traditional GLP-1 receptor pathways.
"These amylin therapies have the properties where this could emerge as a first-line treatment in obesity -- not in all patients but in most patients -- because it's well tolerated, and it's attractive for primary care, who's going to end up treating most of this disease."
— zealand-petrelintide-phase2-zupreme-ada-2026
Zealand Pharma's petrelintide demonstrated robust weight loss with a remarkably low gastrointestinal-related discontinuation rate of just 1.5% zealand-petrelintide-phase2-zupreme-ada-2026. Simultaneously, Novo Nordisk presented strong data for its GLP-1/amylin co-agonist zenagamtide, which achieved a 14.6% mean body weight reduction in patients with Type 2 diabetes as it heads toward Phase 3 novo-nordisk-ada-2026-zenagamtide-cagrisema
.
By targeting distinct neurological pathways, amylin-focused therapies offer a dual path forward: either a standalone option with minimal side effects or a co-formulated partner to GLP-1 that pushes efficacy without adding further gastrointestinal distress. Novo Nordisk is already nearing the commercial finish line with CagriSema, expecting an FDA approval decision in Q4 2026 novo-nordisk-ada-2026-zenagamtide-cagrisema.
What to watch: Watch for the FDA's regulatory decision on CagriSema in Q4 2026, which will mark the commercial debut of the first combined GLP-1/amylin therapy.
What surprised us
- An insurer and PBM giant is completely cutting off its own employees from GLP-1 obesity coverage. Cigna, which operates the major PBM Express Scripts, is ending employee coverage for Wegovy and Zepbound cigna-drops-employee-glp1-coverage-trumprx-cash-pay-2026. It is a stark admission that even the largest players in the prescription supply chain find the commercial costs of these drugs unsustainable for their own workforces.
- Retatrutide causes a bizarre skin sensitivity side effect. Eli Lilly's triple-agonist showed unprecedented weight loss, but it also triggered dysesthesia (abnormal skin sensation/sensitivity) in a striking 12.5% of patients on the 12 mg dose, compared to just 0.9% on placebo retatrutide-phase3-triumph1-results-30-percent.
- Amylin agonists actually reduce pulse rate, reversing a major concern with GLP-1s. While GLP-1 receptor agonists typically increase heart rate, Zealand Pharma's petrelintide was shown to decrease pulse rate while delivering key cardiovascular and metabolic improvements zealand-petrelintide-phase2-zupreme-ada-2026.
Open threads worth a vote
Since last time
The commercial and clinical landscape has shifted significantly. We have moved from a focus on PBM parity and early-stage "triple-G" contenders to a market defined by insurer retrenchment and the clinical trade-offs of high-potency therapies.
- Promoted — Amylin-based therapies: Previously unmentioned, this is now a core pillar of the obesity pipeline.
- Escalated — Efficacy vs. Tolerability: The clinical debate over "super-potency" side effects has moved from a secondary concern to the central narrative of the current clinical data.
- Demoted — None.
- Disappeared — The following topics from the previous briefing are not mentioned:
- Commercial Access: The CVS Caremark/Lilly/Foundayo formulary parity story.
- Kailera Therapeutics: The KAI-4729 triple-G agonist.
- Continuous Sensing: The Abbott/Dexcom hardware pivots.
- Previous Open Threads: All previous threads (Oncology, Medicare Bridge, etc.) have been closed or replaced.
- Unchanged — None.
Commercial Insurance Retreat and the Rise of Cash-Pay (Escalated)
The narrative has shifted from the expansion of commercial access (previously focused on CVS/Lilly parity) to a widespread retrenchment by plan sponsors. Major payers are now abandoning traditional coverage models, pushing patients toward cash-pay and government-discount platforms.
"As availability has increased and new options have emerged, we've made the decision to end our plan's coverage for GLP-1s for weight loss. We remain committed to supporting our employees’ health through a range of weight management programs and resources."
— cigna-drops-employee-glp1-coverage-trumprx-cash-pay-2026
According to Reuters coverage of the June 1, 2026 announcement, Cigna is dropping coverage for Novo Nordisk's Wegovy and Eli Lilly's Zepbound for its own employees cigna-drops-employee-glp1-coverage-trumprx-cash-pay-2026. Employees are being directed to manufacturer direct sites or the federal TrumpRx platform, where brand-name GLP-1s are available for $350 per month and newer oral medications for as low as $150 per month cigna-drops-employee-glp1-coverage-trumprx-cash-pay-2026.
What to watch: Watch whether other major healthcare employers and pharmacy benefit managers follow Cigna's lead in dropping employee weight-loss coverage as the TrumpRx platform gains commercial traction.
Efficacy Milestones Collision with Tolerability Barriers (Escalated)
The clinical focus has moved from early-stage triple-G potency (Kailera) to the realized, long-term data of Eli Lilly's retatrutide, which highlights a critical ceiling: high efficacy is currently tethered to significant gastrointestinal side effects.
"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos. In TRIUMPH-1 and TRANSCEND-T2D-1, treatment with retatrutide resulted in substantial weight reduction together with clinically meaningful improvements in glycemia, knee osteoarthritis pain, and obstructive sleep apnea..."
— retatrutide-phase3-triumph1-results-30-percent
As reported by Fierce Biotech coverage of the ADA sessions, Eli Lilly's retatrutide achieved historic weight loss of 30.3% in its long-term trial extension, but also brought significant tolerability hurdles, particularly at the highest dose, where nausea affected 42.4% of participants retatrutide-phase3-triumph1-results-30-percent. This resulted in an 11.3% discontinuation rate due to adverse events at the maximum 12 mg dose retatrutide-phase3-triumph1-results-30-percent.
What to watch: Watch whether clinicians increasingly favor lower, more tolerable doses of retatrutide over the maximum 12 mg dose in real-world practice.
Amylin Emerges to Challenge GLP-1 Dominance (Promoted)
Amylin-targeting therapies are now a primary focus, positioned as a solution to the tolerability issues plaguing the current GLP-1 market.
"These amylin therapies have the properties where this could emerge as a first-line treatment in obesity -- not in all patients but in most patients -- because it's well tolerated, and it's attractive for primary care, who's going to end up treating most of this disease."
— zealand-petrelintide-phase2-zupreme-ada-2026
Zealand Pharma's petrelintide demonstrated robust weight loss with a remarkably low gastrointestinal-related discontinuation rate of just 1.5% zealand-petrelintide-phase2-zupreme-ada-2026. Novo Nordisk also presented strong data for its GLP-1/amylin co-agonist zenagamtide, which achieved a 14.6% mean body weight reduction in patients with Type 2 diabetes as it heads toward Phase 3 novo-nordisk-ada-2026-zenagamtide-cagrisema.
What to watch: Watch for the FDA's regulatory decision on CagriSema in Q4 2026, which will mark the commercial debut of the first combined GLP-1/amylin therapy.
What surprised us
- An insurer and PBM giant is completely cutting off its own employees from GLP-1 obesity coverage. [NEW] Cigna, which operates the major PBM Express Scripts, is ending employee coverage for Wegovy and Zepbound cigna-drops-employee-glp1-coverage-trumprx-cash-pay-2026. It is a stark admission that even the largest players in the prescription supply chain find the commercial costs of these drugs unsustainable for their own workforces.
- Retatrutide causes a bizarre skin sensitivity side effect. [NEW] Eli Lilly's triple-agonist showed unprecedented weight loss, but it also triggered dysesthesia (abnormal skin sensation/sensitivity) in a striking 12.5% of patients on the 12 mg dose, compared to just 0.9% on placebo retatrutide-phase3-triumph1-results-30-percent.
- Amylin agonists actually reduce pulse rate, reversing a major concern with GLP-1s. [NEW] While GLP-1 receptor agonists typically increase heart rate, Zealand Pharma's petrelintide was shown to decrease pulse rate while delivering key cardiovascular and metabolic improvements zealand-petrelintide-phase2-zupreme-ada-2026.
Open threads